Summary
• TherapeuticsMD, Inc. shares declined by 10.7% to $1.59 following its Q3 2025 earnings report.
• The company reported a slight net income of $50 thousand, missing market forecasts by 45.4%.
• Despite recent volatility, analysts maintain a “Buy” rating on the stock, indicating a positive long-term outlook.
TherapeuticsMD, Inc. (NASDAQ: TXMD) is experiencing an intraday decline of 10.7%, with shares priced at $1.59. This comes as the stock continues to react to its recent earnings report, in which the company reported a slight net income from continuing operations.
Earnings Report Highlights Earnings Performance
On November 12, 2025, TherapeuticsMD announced its financial results for the third quarter of 2025. The company reported net income from continuing operations of $50 thousand, translating to $0.00 per basic and diluted share, a significant improvement from a net loss of $567 thousand, or $0.05 per share, in the prior year. Despite this positive shift, results fell short of market forecasts, leading to a notable pullback in share price today.
The latest earnings call showed a surprise of -45.4% when compared to the expected earnings estimate of $0.04. This trend of missing consensus estimates has raised investor concerns, contributing to today’s price movement amid the ongoing scrutiny of its financial performance.
Recent SEC Filing and Additional Information
Following its earnings report, the company filed an 8-K form on November 13, 2025, detailing the financial results. Although the filing provides important updates regarding financial figures, it has not contributed positively to investor sentiment in the current trading session.
Market Performance and Technical Overview
As of the latest trading session, TXMD shows a notable decline in price with a last reported volume of 123,334 shares, which is above its average volume for the last 10 days of 261,530. The stock has seen volatility with a weekly performance uptick of 16.8% and a monthly gain of 31.1%, but year-to-date, it remains up by 61.6%.
Technical indicators reveal an RSI of 61.2, suggesting it is nearing overbought territory. The 20-day and 50-day moving averages currently reflect deviations of 22.7% and 43.6%, respectively, indicating a potential correction in price following today’s significant downturn.
Analyst Sentiment
The stock still holds a “Buy” rating among analysts, which reflects a generally favorable long-term outlook despite the recent volatility and earnings miss. The divergence between analyst sentiment and market performance underscores the challenges TherapeuticsMD faces in translating financial results into sustained investor confidence.
With shares slipping following less-than-expected earnings results, investors are closely monitoring TherapeuticsMD’s operational strategy and market conditions for signs of recovery.